Trial · NCT07910682
Bioequivalence of Sitagliptin/Metformin Tablets in Healthy Chinese Adults Under Fasting and Fed Conditions
NCT07910682, Phase 1, Completed, Guangzhou Panyu Central Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bioequivalence of Sitagliptin/Metformin Tablets in Healthy Chinese Adults Under Fasting and Fed Conditions. Trials, record NCT07910682. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910682
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bioequivalence of Sitagliptin/Metformin Tablets in Healthy Chinese Adults Under Fasting and Fed Conditions
- NCT number
- NCT07910682
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 56 participants, actual
- Lead sponsor
- Guangzhou Panyu Central Hospital
- Conditions
- Healhty
- Interventions
- Sitagliptin/metformin hydrochloride tablets (50 mg/850 mg), Sitagliptin/metformin hydrochloride reference tablets (50 mg/850 mg)
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cmax of sitagliptin | Pre-dose and up to 48 hours post-dose in each treatment period. | Peak plasma concentration of sitagliptin, derived from plasma concentration-time data by non-compartmental analysis. |
| Primary | AUC0-t of sitagliptin | Pre-dose and up to 48 hours post-dose in each treatment period. | Area under the plasma concentration-time curve of sitagliptin from time zero to the last quantifiable concentration, calculated by non-compartmental analysis. |
| Primary | AUC0-inf of sitagliptin | Pre-dose and up to 48 hours post-dose in each treatment period. | Area under the plasma concentration-time curve of sitagliptin from time zero extrapolated to infinity, calculated by non-compartmental analysis. |
| Primary | Cmax of metformin | Pre-dose and up to 48 hours post-dose in each treatment period. | Peak plasma concentration of metformin, derived from plasma concentration-time data by non-compartmental analysis. |
| Primary | AUC0-t of metformin | Pre-dose and up to 48 hours post-dose in each treatment period. | Area under the plasma concentration-time curve of metformin from time zero to the last quantifiable concentration, calculated by non-compartmental analysis. |
| Primary | AUC0-inf of metformin | Pre-dose and up to 48 hours post-dose in each treatment period. | Area under the plasma concentration-time curve of metformin from time zero extrapolated to infinity, calculated by non-compartmental analysis. |
| Secondary | Tmax of sitagliptin and metformin | Pre-dose and up to 48 hours post-dose in each treatment period. | Time to reach peak plasma concentration of sitagliptin and metformin, obtained directly from the concentration-time data. |
| Secondary | Number of participants with adverse events | Pre-dose and up to 48 hours post-dose in each treatment period. | Incidence, severity, and relationship to study drug of adverse events, assessed from vital signs, physical examination, 12-lead electrocardiogram, and clinical laboratory tests. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910682
GET https://conductscience.org/api/trials/v1/NCT07910682/registered